Deals

Eight Qualities Funders Look for in the Seed Stage

By Rich Kirkner | August 16, 2017

Candor, passion, realism, talent, flexibility, self awareness, humility, and focus are all qualities seed-stage benefactors look for in a start-up founder, a panel of fund…

Major Ophthalmic Pipeline Developments Drive OIS Index in July

By Michael Lachman | August 1, 2017

In October, we launched the OIS Index, a composite of ophthalmic growth stocks, to track the investment performance of our sector. Our goal is to…

First-Half Performance: OIS Index Tracks US Stock Market but Lags Healthcare Benchmarks

By Michael Lachman | July 5, 2017

We see ophthalmology as one of the more innovative specialties in healthcare, but does that excitement translate to the public markets? In October, we launched…

OIS Index Declines in May Despite Positive Pipeline News from Aerie

By Michael Lachman | June 1, 2017

In October, we launched the OIS Index, a composite of ophthalmic growth stocks, to track the investment performance of our sector. Our goal is to…

OIS Index Posts Third Straight Positive Month in April

By Michael Lachman | May 1, 2017

In October, we launched the OIS Index, a composite of ophthalmic growth stocks, to track the investment performance of our sector. Our goal is to…

OIS Index Tracks Flat US Stock Market and Healthcare Sector Performance in March

By Michael Lachman | March 31, 2017

In October, we launched the OIS Index, a composite of ophthalmic growth stocks, to track the investment performance of our sector. Our goal is to…

Allergan Makes a Play in Gene Editing

By Rich Kirkner | March 22, 2017

With its licensing agreement to develop genome-editing programs with Editas Medicine to treat retinal diseases, Allergan has made a move to partner with one of…

Deal between Minnesota Eye Consultants and Waud Capital Signals Change Coming to Ophthalmology

By Tom Salemi | March 3, 2017

Two years ago, the principals at Minnesota Eye Consultants recognized the time had come to find a way to expand the practice. But doing so…

OIS Index Rebounds – Delivers Positive Performance in February

By Michael Lachman | March 2, 2017

In October, we launched the OIS Index, a composite of ophthalmic growth stocks, to track the investment performance of our sector. Our goal is to…

Roche/Genentech’s Second Move to Protect Lucentis Franchise

By Steve Lenier | February 15, 2017

With its patents on Lucentis set to expire in a few years and clinical trials of at least three Lucentis biosimilars underway, Roche’s recent acquisition…